Androgen receptors frequently are expressed in breast carcinomas - Potential relevance to new therapeutic strategies
Androgen receptors frequently are expressed in breast carcinomas - Potential relevance to new therapeutic strategies
复制标题
作者：
Moinfar, F;Okcu, M;Denk, H
背景一些研究已经证明了雌激素和孕激素受体（ER和PR）在乳腺癌中的生物学和治疗意义。本研究的目的是检测乳腺癌中雄激素受体（AR）的存在。200例乳腺癌，包括145例浸润性和55例非浸润性（导管原位癌[DCIS]）病变，使用抗AR单克隆抗体对福尔马林固定，石蜡包埋的档案材料进行了检查。分析结果与化学方法测定的ER、PR和HER-2/neu表达的相关性。根据国际标准化指南，145例浸润性癌中的87例（60%）和55例DCIS中的45例（82%）为AR阳性。绝大多数I级癌为AR阳性（90%的I级浸润性癌和95%的I级DCIS），而在3级浸润性癌和DCIS中，分别在46%和76%的病例中观察到AR阳性免疫反应。在3级癌病例中，33例浸润性癌（39%）和17例DCIS病变（68%）为ER阴性但AR阳性。在I级癌（浸润性和DCIS）中，没有一例HER-2/neu阳性，但大多数病例AR强阳性。相反，许多浸润性3级癌显示AR状态和HER-2/neu状态之间的一致性（AR阳性和HER-2/neu阳性，30.5%; AR阴性和HER-2/neu阴性，42.5%）。雄激素受体通常在DCIS和浸润性乳腺癌中表达。相当数量的低分化癌为ER阴性和PR阴性，但AR阳性。AR的免疫组织化学检查是可取的，因为它将提供更多的信息类固醇受体在乳腺癌。
BACKGROUND. Several studies have demonstrated the biologic and therapeutic significance of estrogen and progesterone receptors (ER and PR) in breast carcinomas. The aim of the current study was to examine the presence of androgen receptors (AR) in breast carcinomas.METHODS. Two hundred cases of breast carcinoma, consisting of 145 invasive and 55 noninvasive (ductal carcinoma in situ [DCIS]) lesions, were examined using a monoclonal antibody against AR on formalin-fixed, paraffin-embedded archival material. The results were analyzed for correlations with immunohistochemically determined ER, PR, and HER-2/neu expression.RESULTS. Eighty-seven of the 145 cases (60%) of invasive carcinoma and 45 of the 55 cases (82%) of DCIS were AR-positive according to internationally standardized guidelines. The vast majority of Grade I carcinomas were positive for AR (90% of invasive Grade I carcinomas and 95% of Grade I DCIS), whereas in Grade 3 invasive carcinomas and DCIS, positive immunoreactions for AR were observed in 46% and 76% of cases, respectively. Among the cases of Grade 3 carcinoma, 33 invasive carcinomas (39%) and 17 DCIS lesions (68%) were ER-negative but AR-positive. Among Grade I carcinomas (invasive and DCIS), not a single case was positive for HER-2/neu, but most cases were intensely positive for AR. In contrast, many invasive Grade 3 carcinomas exhibited agreement between AR status and HER-2/neu status (AR-positive and HER-2/neu-positive, 30.5%; AR-negative and HER-2/neu-negative, 42.5%).CONCLUSIONS. Androgen receptors are commonly expressed in DCIS and in invasive breast carcinoma. A significant number of poorly differentiated carcinomas are ER-negative and PR-negative but AR-positive. Immunohistochemical examination of AR would be desirable because it would provide additional information about steroid receptors in breast carcinomas.